Navigation Links
HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
Date:9/4/2007

- Collaborative studies will use HistoRx AQUA(R)-based assays to evaluate clinical utility of protein biomarkers for predicting treatment response

and outcome in brain tumors -

NEW HAVEN, Conn., Sept. 4 /PRNewswire/ -- HistoRx, Inc., announced today that it has entered into a research collaboration with the Radiation Therapy Oncology Group (RTOG), a National Cancer Institute-funded clinical cooperative group. Under the terms of the agreement, HistoRx will provide RTOG researchers access to HistoRx's AQUA(R) technology for biomarker analysis and will develop customized immunohistochemical assays to be used by RTOG in investigating the relationship between specific protein biomarkers and clinical responsiveness in brain tumor patients. HistoRx intends to commercialize assays and reagents developed in the course of the collaboration for clinical use as predictive diagnostics.

The RTOG studies will use a combination of high-throughput tissue microarrays, multiplex analysis, and AQUA(R) analysis-based assays to determine whether brain tumor patients are likely to respond to a specific targeted therapy and whether the biomarkers under investigation may be used to predict survival.

"We selected HistoRx's AQUA(R) technology based on its unique ability to measure protein biomarker expression and localization in diseased tissue sections in a precisely quantitative, reproducible, and standardized way," said Arnab Chakravarti, MD, of Massachusetts General Hospital and a member of the RTOG Translational Research Program. "By eliminating the subjective interpretation inherent in conventional qualitative immunohistochemical analysis, we expect this collaboration will provide a substantial boost to our research in brain cancer by enabling RTOG researchers to reveal stronger, more reliable statistical correlations linking protein biomarker expression with prediction of patient response to therapy and disease outcome."

"As the relationship between protein expression patterns and disease gains an expanding role in new drug and diagnostic development and in the way physicians treat patients and individualize therapeutic regimens, we continue to advance our goal of replacing conventional immunohistochemistry with AQUA(R) analysis, a more precise and consistent tool that is enabling pathologists and clinicians to integrate data from predictive biomarker studies confidently into research, diagnosis, and patient treatment," said Rana K. Gupta, CEO of HistoRx. "We are pleased to have reached this agreement with such a renowned organization as The Radiation Therapy Oncology Group and to have its endorsement of the AQUA(R) technology's predictive power and potential for developing companion diagnostic and prognostic assays."

About HistoRx (http://www.historx.com)

HistoRx is a systems pathology company developing and commercializing quantitative biomarker analysis technology that provides exceptional measurement and localization of proteins in their natural context within tissue. The pioneering HistoRx proprietary AQUA(R) (Automated Quantitative Analysis) technology is the first platform capable of measuring biomarker concentration with subcellular resolution to generate more precise, efficient answers about the safety and effectiveness of new therapeutics in development and to enable development of companion diagnostic tests for targeted therapies. HistoRx services are used by pharmaceutical and biotechnology companies throughout the drug discovery, preclinical study, and clinical development continuum. HistoRx has two lines of diagnostic products in development: HistoRx companion diagnostic products are linked to partners' drug candidates in development to predict prognostic outcome; and HistoRx is independently developing AQUA(R)-based diagnostics for the clinical diagnosis, prognosis, and treatment management of complex diseases.

About RTOG

The Radiation Therapy Oncology Group (RTOG) is a clinical research enterprise of the American College of Radiology (ACR), located in the ACR Philadelphia, PA office. RTOG is a multi-institutional international clinical cooperative group funded primarily by the National Cancer Institute. RTOG has over 35 years of experience in conducting clinical trials and is comprised of over 280 major research institutions in the United States and Canada. The group currently is conducting more than 40 active studies that involve radiation therapy alone or in conjunction with surgery and/or chemotherapeutic drugs or which investigate quality of life issues and their effects on the cancer patient.

CONTACT: Mary Moynihan

M2Friend Biocommunications

(802) 951-9600

mary@m2friend.com


'/>"/>
SOURCE HistoRx, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Aeolus Pharmaceuticals AEOL 10113 May Play an Important Role Regulating the Oxidative Damage Induced by Ionizing Radiation
2. Aeolus Pharmaceuticals AEOL 10113 Demonstrates Potential as a Protector of Healthy Normal Cells from Cancer Radiation Therapy
3. Viventia biotech reports synergystic effect of its Proxinium antibody in combinaton with chemotherapy and radiation
4. Cleveland BioLabs Protectan CBLB502 Demonstrates Strong Survival Benefits as Mitigator Against Radiation-Induced Damage in Study
5. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
6. Hollis-Eden Announces Cancellation of Acute Radiation Syndrome RFP by Department of Health and Human Services
7. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
8. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
9. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
10. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
11. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... MOUNTAIN VIEW, Calif. , Dec. 8, 2016 ... it intends to offer newly issued shares of common stock, ... "Shares") pursuant to an underwritten public offering.  The final terms ... at the time of pricing, and there can be no ... completed. IRIDEX expects to use the net proceeds ...
(Date:12/8/2016)... -- Australia Glaucoma Surgery Devices Market Outlook to ... Glaucoma Surgery Devices Market Outlook to 2022", provides ... Devices market. The report provides value, in millions ... prices (USD) within market segement - Glaucoma Drainage ... and distribution shares data for each of these ...
(Date:12/8/2016)...  The global biosurgery market is expected to grow ... of 2016 to 2021. The market is poised to ... billion in 2016. The market is primarily driven by ... injuries and spinal problems, increasing clearance of biosurgery products ... loss management. In this report, the biosurgery ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... The Florida Hospital Tampa Wound ... Medical Society (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies the ... hospitals and facilities have earned this distinction. This is the second time the ...
(Date:12/8/2016)... Pennsylvania (PRWEB) , ... December 08, 2016 , ... ... Duck Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which ... , “This was our first franchise-wide Quack Gives Back initiative, ...
(Date:12/8/2016)... and JENNERSVILLE, Pa. (PRWEB) , ... December 08, ... ... that Penn Medicine Southern Chester County, a Property owned by an affiliate of ... million, 72,000 square foot Penn Medicine Southern Chester County ambulatory care center (ACC) ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s ... groups, has aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced ... J. Hennessy, Jr said, “CURE Media Group is honored to team up with Upstage ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , ... firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the ... series, and attorneys from the firm’s global Life Sciences & Medical Technology Group have ...
Breaking Medicine News(10 mins):